inactivated-adjuvanted SARS-CoV-2 virus vaccine
Showing 26 - 50 of >10,000
COVID-19 Vaccine Trial in Argentina (Gamma Variant RBD-based ARVAC-CG vaccine, Omicron Variant RBD-based ARVAC-CG vaccine,
Recruiting
- COVID-19 Vaccine
- Gamma Variant RBD-based ARVAC-CG vaccine
- +3 more
-
Argentina, C.a.b.a., ArgentinaCentro de Educación Médica e Investigaciones Clínicas "Norberto
Feb 28, 2023
COVID-19 Trial in Xuzhou (Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule, Two
Completed
- COVID-19
- Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule
- +11 more
-
Xuzhou, Jiangsu, ChinaSuining County Center for Disease Control and Prevention
Feb 22, 2022
COVID-19 Pandemic Trial in Zhuhai (Recombinant SARS-CoV-2 Fusion Protein Vaccine 10µg, Recombinant SARS-CoV-2 Fusion Protein
Active, not recruiting
- COVID-19 Pandemic
- Recombinant SARS-CoV-2 Fusion Protein Vaccine 10μg
- +2 more
-
Zhuhai, Guangdong, ChinaZhuhai Peoples' Hospital Medical Group
Mar 12, 2022
COVID-19 Trial (GamCovidVac-M vector vaccine for the prevention of COVID-19 with altered antigenic composition)
Not yet recruiting
- COVID-19
- GamCovidVac-M vector vaccine for the prevention of COVID-19 with altered antigenic composition
- (no location specified)
Oct 4, 2023
COVID-19, Rabies Trial in Guiyang, Taiyuan (coadministration, COVID-19 vaccine, rabies vaccine)
Recruiting
- COVID-19
- Rabies
- coadministration
- +2 more
-
Guiyang, China
- +1 more
Jul 27, 2022
COVID-19 Pandemic, COVID-19 Vaccines Trial in Jember, Malang, Surabaya (Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell
Recruiting
- COVID-19 Pandemic
- COVID-19 Vaccines
- Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) 5 µg
- CoronaVac Biofarma COVID-19 Vaccine
-
Jember, East Java, Indonesia
- +4 more
Aug 18, 2022
Covid19 Trial in Lenexa, Raleigh (Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 1, Single Dose, Intranasal
Recruiting
- Covid19
- Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 1, Single Dose, Intranasal Drops
- +4 more
-
Lenexa, Kansas
- +1 more
Aug 1, 2022
SARS-CoV-2 Vaccination on Cancer Patients Infected With
Recruiting
- COVID-19 Infection
- COVID-19 Vaccine
- no intervention
-
Beijing, Beijing, ChinaSanhuan Cancer Hospital, Chaoyang District, Beijing(Cancer Hospi
Mar 7, 2023
COVID-19 Trial in Huai'an (Inactivated SARS-CoV-2 Vaccine (Vero cell))
Completed
- COVID-19
- Inactivated SARS-CoV-2 Vaccine (Vero cell）
-
Huai'an, Jiangsu, ChinaJingliang Wu
Apr 12, 2022
COVID-19 Trial (GamCovidVac vector vaccine for the prevention of COVID-19 (with altered antigenic profile))
Not yet recruiting
- COVID-19
- GamCovidVac vector vaccine for the prevention of COVID-19 (with altered antigenic profile)
- (no location specified)
Oct 4, 2023
Inactivated COVID-19 Vaccine of the First Booster Dose
Active, not recruiting
- COVID-19
- COVID-19 Vaccine (Vero Cell), Inactivated
-
Manguinhos, BrazilInstituto Nacional de Infectologia Evandro Chagas (INI-FIOCRUZ)
Jan 11, 2023
Covid19, Vaccines Trial in Santiago (SARS-CoV-2 inactivated vaccine)
Active, not recruiting
- Covid19
- Vaccines
- SARS-CoV-2 inactivated vaccine
-
Santiago, RM, ChileCentro de Especialidades Médicas, Red de Salud UC Christus
Jun 20, 2022
COVID-19 Trial in Xinqi (High-dosage SARS-CoV-2 vaccine, Medium-dosage SARS-CoV-2 vaccine)
Active, not recruiting
- COVID-19
- High-dosage SARS-CoV-2 vaccine
- Medium-dosage SARS-CoV-2 vaccine
-
Xinqi, Jiangsu, ChinaXinqi City Center for Disease Control and Prevention
Feb 13, 2022
COVID-19 Trial in Changsha (Recombinant Novel Coronavirus vaccine (CHO Cells))
Completed
- COVID-19
- Recombinant Novel Coronavirus vaccine (CHO Cells)
-
Changsha, Hunan, ChinaHunan Provincial Center for Disease Control and Prevention
Jun 6, 2023
COVID-19 Trial in Shijiazhuang (Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28, Two doses of
Active, not recruiting
- COVID-19
- Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28
- +2 more
-
Shijiazhuang, Hebei, ChinaZanhuang county Center for Disease Control and Prevention
Apr 12, 2022
Covid-19 Vaccine Trial (PIKA COVID-19 vaccine)
Not yet recruiting
- Covid-19 Vaccine
- PIKA COVID-19 vaccine
- (no location specified)
Jul 17, 2022
COVID-19 Trial in Kyiv, Vinnitsa (CpG 1018/Alum-adjuvanted SCB-2019 vaccine, Havrix, Placebo; 0.9% saline)
Terminated
- COVID-19
- CpG 1018/Alum-adjuvanted SCB-2019 vaccine
- +2 more
-
Kyiv, Ukraine
- +3 more
May 19, 2022
Immunogenicity, Safety Trial (Phase II:SWIM816;SARS-Cov-2;, Phase II:SW-BIC-213;SARS-Cov-2;, PhaseIII:SWIM816;SARS-Cov-2;)
Not yet recruiting
- Immunogenicity
- Safety
- Phase II:SWIM816;SARS-Cov-2;
- +3 more
- (no location specified)
Jun 18, 2023
COVID-19 Trial in Bloemfontein, Pretoria, Soweto (Candidate vaccine, SCB-2020S, Candidate vaccine, SCB-2019, Squalene based
Active, not recruiting
- COVID-19
- Candidate vaccine, SCB-2020S
- +3 more
-
Bloemfontein, South Africa
- +2 more
Oct 18, 2022
Covid19 Trial in Jakarta (SARS-CoV-2 Protein Subunit Recombinant Vaccine, SARS-CoV-2 Inactivated Vaccine)
Completed
- Covid19
- SARS-CoV-2 Protein Subunit Recombinant Vaccine
- SARS-CoV-2 Inactivated Vaccine
-
Jakarta, Greater Jakarta, IndonesiaFakultas Kedokteran Universitas Indonesia
Aug 8, 2022
SARS-CoV-2 Trial in Islamabad (SARS-CoV-2 Bivalent mRNA vaccine (LVRNA021), 0.9% sodium chloride solution)
Recruiting
- SARS-CoV-2
- SARS-CoV-2 Bivalent mRNA vaccine (LVRNA021)
- 0.9% sodium chloride solution
-
Islamabad, PakistanSindh Infectious Diseases Hospital & Research Center Dow Univers
Apr 16, 2023
COVID-19 Vaccine, COVID-19 Trial in Bangkok (50 µg Baiya SARS-CoV-2 Vax 2, Placebo)
Not yet recruiting
- COVID-19 Vaccine
- COVID-19
- 50 μg Baiya SARS-CoV-2 Vax 2
- Placebo
-
Bangkok, ThailandQueen Saovabha Memorial Institute
May 23, 2023
COVID-19 Trial (LYB001, Placebo)
Not yet recruiting
- COVID-19
- LYB001
- Placebo
- (no location specified)
Oct 26, 2022
COVID-19 Trial in Wong Chuk Hang (SARS-CoV-2 DNA Vaccine (ICCOV))
Recruiting
- COVID-19
- SARS-CoV-2 DNA Vaccine (ICCOV)
-
Wong Chuk Hang, Hong KongGleneagles Hospital Hong Kong
Jun 16, 2023
Immunogenicity, Safety, Efficacy Trial in Savannakhét (SW-BIC-213;SARS-Cov-2., Sinopharm (BIBP);SARS-Cov-2.,
Active, not recruiting
- Immunogenicity
- +2 more
- SW-BIC-213;SARS-Cov-2.
- +2 more
-
Savannakhét, Sava, Lao People's Democratic RepublicSavannakhét Provincial hospital
Jan 8, 2023